Can mycotoxins and organophosphates impair blood-brain barrier integrity?

Mycotoxins and organophosphates have biologically credible potential to affect brain-endothelial function, but the full exposure-to–blood-brain barrier (BBB) pathway remains primarily experimental rather than demonstrated in people.

Experimental and clinical evidence

• Mycotoxins: Ochratoxin A (OTA) increased reactive oxygen species and inflammatory signaling in experimental systems. In cultured brain-endothelial models, OTA at 1–10 µM reduced barrier tightness and increased paracellular permeability. Cross-sectional human biomonitoring has associated detection of some mycotoxins with higher oxidative-stress markers, but cannot establish causation.
• Organophosphates: Cell and animal studies consistently report increased reactive oxygen species, lipid peroxidation, and impaired antioxidant defenses. Similar oxidative-stress markers have been described in occupationally exposed populations. Experimental BBB models found that malathion/malaoxon and chlorpyrifos/oxon can reduce endothelial barrier integrity; an organophosphate oxon reduced tight-junction protein expression and increased permeability above a concentration threshold.

Mechanistic interpretation

• Oxidative stress and inflammatory signaling are plausible mediators of BBB disruption. Relevant toxicants produce endothelial reactive oxygen species alongside reduced tightness and greater permeability, consistent with injury to tight-junction–dependent barrier function.
• OTA provides the clearest integrated experimental example: reactive oxygen species, inflammatory responses, and impaired endothelial barrier properties occur together. Organophosphate-associated inflammatory signaling is biologically coherent but less directly established in well-controlled human studies.

Interpretation for real-world exposure

• Human evidence does not yet show that typical mycotoxin or organophosphate exposure causes BBB injury through oxidative stress or inflammation. In particular, urinary dialkyl phosphate metabolites are nonspecific exposure indicators and cannot identify a particular organophosphate or establish downstream barrier injury.

Bottom line

• The claim is plausible: both exposure classes can promote oxidative stress experimentally, OTA can promote inflammatory signaling, and each has experimental evidence of endothelial BBB impairment. However, a causal oxidative/inflammatory pathway leading to human BBB dysfunction remains unproven.